^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

inezetamab (AMG994)

i
Other names: AMG 994, AMG994, AMG-994
Associations
Company:
Amgen, BeiGene
Drug class:
Mesothelin inhibitor, CD40 agonist
Associations
1year
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=11, Completed, Amgen | Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Jun 2023
Trial completion • Trial completion date • Combination therapy • Metastases
|
MSLN (Mesothelin)
|
MSLN expression • MSLN positive
|
inezetamab (AMG994) • zeluvalimab (AMG 404)
over1year
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=11, Active, not recruiting, Amgen | Trial completion date: Aug 2024 --> Sep 2023 | Trial primary completion date: Feb 2024 --> Jun 2023
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
MSLN (Mesothelin)
|
MSLN expression • MSLN positive
|
inezetamab (AMG994) • zeluvalimab (AMG 404)
2years
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=11, Active, not recruiting, Amgen | Trial completion date: Mar 2023 --> Aug 2024 | Trial primary completion date: Jan 2023 --> Feb 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
MSLN (Mesothelin)
|
MSLN expression • MSLN positive
|
inezetamab (AMG994) • zeluvalimab (AMG 404)
over2years
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=11, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | N=214 --> 11 | Trial completion date: Aug 2025 --> Mar 2023 | Trial primary completion date: Feb 2025 --> Jan 2023
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
MSLN (Mesothelin)
|
MSLN expression • MSLN positive
|
inezetamab (AMG994) • zeluvalimab (AMG 404)
over2years
Trial primary completion date • Combination therapy
|
MSLN (Mesothelin)
|
MSLN expression • MSLN positive
|
inezetamab (AMG994) • zeluvalimab (AMG 404)
almost3years
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=214, Recruiting, Amgen | Trial completion date: Oct 2024 --> Aug 2025 | Trial primary completion date: Oct 2024 --> Aug 2025
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
MSLN (Mesothelin)
|
MSLN expression • MSLN positive
|
inezetamab (AMG994) • zeluvalimab (AMG 404)